- Home
- AVIR vs NKTX Comparison
AVIR vs NKTX Comparison
Compare AVIR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- NKTX
- Stock Information
- Founded
- AVIR 2012
- NKTX 2015
- Country
- AVIR United States
- NKTX United States
- Employees
- AVIR N/A
- NKTX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- NKTX Health Care
- Exchange
- AVIR Nasdaq
- NKTX Nasdaq
- Market Cap
- AVIR 273.0M
- NKTX 123.5M
- IPO Year
- AVIR 2020
- NKTX 2020
- Fundamental
- Price
- AVIR $3.67
- NKTX $1.67
- Analyst Decision
- AVIR Hold
- NKTX Strong Buy
- Analyst Count
- AVIR 1
- NKTX 6
- Target Price
- AVIR $6.00
- NKTX $14.40
- AVG Volume (30 Days)
- AVIR 410.2K
- NKTX 505.0K
- Earning Date
- AVIR 08-06-2025
- NKTX 08-12-2025
- Dividend Yield
- AVIR N/A
- NKTX N/A
- EPS Growth
- AVIR N/A
- NKTX N/A
- EPS
- AVIR N/A
- NKTX N/A
- Revenue
- AVIR N/A
- NKTX N/A
- Revenue This Year
- AVIR N/A
- NKTX N/A
- Revenue Next Year
- AVIR N/A
- NKTX N/A
- P/E Ratio
- AVIR N/A
- NKTX N/A
- Revenue Growth
- AVIR N/A
- NKTX N/A
- 52 Week Low
- AVIR $2.46
- NKTX $1.31
- 52 Week High
- AVIR $4.15
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- AVIR 76.11
- NKTX 39.70
- Support Level
- AVIR $3.15
- NKTX $1.70
- Resistance Level
- AVIR $3.35
- NKTX $1.84
- Average True Range (ATR)
- AVIR 0.13
- NKTX 0.09
- MACD
- AVIR 0.03
- NKTX -0.02
- Stochastic Oscillator
- AVIR 83.81
- NKTX 2.38
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.